Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Approves Keytruda, Leqembi SC Formulations, Xcopri, and More Drugs
Japan’s health ministry on September 16 granted regulatory approvals for a slew of new medicines and indications, including subcutaneous formulations of MSD’s Keytruda (pembrolizumab) and Eisai’s Leqembi (lecanemab). MSD’s SC product Keyject, known as Keytruda Qlex in the US, combines…
To read the full story
Related Article
REGULATORY
- Pharma Groups Press for Freeze on CEA Price Cuts, Cite Unresolved Issues
September 17, 2026
- Japan Approves Keytruda, Leqembi SC Formulations, Xcopri, and More Drugs
September 17, 2026
- Shionogi ADHD App to Go Out-of-Pocket after 2 Treatment Cycles
September 17, 2026
- Japan Cabinet Approves Food Tax Cut Outline; 1% Rate for 2 Years
September 16, 2026
- MHLW to Track Prescription Shifts under OTC-Like Drug Charge
September 16, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…